Sangamo Biosciences (SGMO) Smashed After Drug Fails In Mid-Stage Trial
Tweet Send to a Friend
Shares of Sangamo Biosciences Inc. (Nasdaq: SGMO) are 60% lower in pre-open trading this morning after the company's nerve drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
